Yes, Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in adults with a BMI of 30 kg/m or higher, or 27 kg/m or higher with at least one weight-related comorbidity such as hypertension or dyslipidemia
At 8 mg, the relative risk jumped to 2.51, with a confidence interval of 1.26 to 5.00 and a statistically significant P value of 0.009
Pharmacogenet Genomics 21:837850 Christensen MM, Brasch-Andersen C, Green H (2015) The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c: corrigendum
Promising signals are a starting point for investigation not a substitute for robust human efficacy data
Yes, and this is a common treatment pathway
N=1,961 adults with obesity